Logo

Merck Licenses Ingenuity Pathways Analysis Software

Dec 06, 2004

NEW YORK, Dec. 6 (GenomeWeb News) - Merck has taken a multi-year license to Ingenuity's Pathways Analysis software for use by its scientists worldwide, the companies said today.

 

Under the multi-year license, Merck plans to use the application, which contains information about biological networks and pathways curated from the scientific literature, together with its own tools for molecular profiling.

 

Merck will also integrate Ingenuity Pathways Analysis with its own bioinformatics systems.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.